Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation

Liver Transplantation and Surgery

Volumn 5, Issue 6, 1999, Pages 491-496

  Yao, F Y ^a   Osorio, R W ^a   Roberts, J P ^a   Poordad, F F ^a   Briceno, M N ^a   Garcia Kennedy, R ^a   Gish, R R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; LAMIVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; INFECTION PREVENTION; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENT INFECTION; TREATMENT OUTCOME;

EID: 0032722346     PISSN: 10743022     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.500050605     Document Type: Article

References (34)

1. 1 Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung J, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus–related liver disease. Hepatology 1991 ; 13: 619–626. MEDLINE
2. 2 O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, et al. Hepatitis B virus reinfection after orthotopic liver transplantation: Serologic and clinical implications. J Hepatol 1992 ; 14: 104–111. MEDLINE
3. 3 Lake JR, Wright TL. Liver transplantation for patients with hepatitis B: What have we learned from our results? Hepatology 1991 ; 13: 796–799. MEDLINE
4. 4 Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJ. Hepatic histologic findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991 ; 13: 150–157. MEDLINE
5. 5 Samuel D, Müller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993 ; 329: 1842–1847. MEDLINE
6. 6 Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, et al. Passive immunoprophylaxis after liver transplantation in HBsAg‐positive patients. Lancet 1991 ; 337: 813–815. MEDLINE
7. 7 Müller R, Gubernatis G, Farle M, Nichoff G, Klein H, Wittekind G, et al. Liver transplantation in HBs antigen (HBsAg) carriers: Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 1991 ; 13: 90–96. MEDLINE
8. 8 Lemmens HP, Langrehr JM, Blumhardt G, Lohmann R, Knopp M, Verschl J, et al. Outcome following orthotopic liver transplantation in HBsAg‐positive patients using short‐ or long‐term immunoprophylaxis. Transplant Proc 1994 ; 26: 3622–3623. MEDLINE
9. 9 Langrehr JM, Lemmens HP, Keck H, Lohmann R, Knopp M, Neumann U, et al. Liver transplantation in hepatitis B surface antigen–positive patients with postoperative long‐term immunoprophylaxis. Transplant Proc 1995 ; 2: 418–425.
10. 10 Grazi GL, Mazziotti A, Sama C, Jovine E, Stefanini F, Paladini R, et al. Liver transplantation in HBsAg‐positive HBV DNA–negative cirrhotics: Immunoprophylaxis and long‐term outcome. Liver Transpl Surg 1996 ; 2: 418–425. MEDLINE
11. 11 Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996 ; 24: 1327–1333. MEDLINE
12. 12 McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis cirrhosis with aggressive passive immunization. Transplantation 1996 ; 61: 1358–1364. MEDLINE
13. 13 Lake JR. Should liver transplantation be performed for patients with chronic hepatitis B? Liver Transpl Surg 1995 ; 1: 260–265. MEDLINE
14. 14 Poterucha JL, Wiesner RH. Liver transplantation and hepatitis B. Ann Intern Med 1997 ; 125: 805–807.
15. 15 Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998 ; 27: 213–222. MEDLINE
16. 16 Protzer‐Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer Zum, Büschenfelde KH, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high‐dose hepatitis B immune globulin after liver transplantation. Hepatology 1998 ; 27: 254–263. MEDLINE
17. 17 Samuel D, Roche B, Feray C, Arulnaden JI, Gigon M, Bismuth A, et al. Long‐term results of liver transplantation in HBsAg‐positive patients receiving anti‐HBsAg passive immunoprophylaxis [abstract]. Hepatology 1998 ; 28: 313A.
18. 18 Lai CL, Chien RN, Leung NWY, Chang TT, Guang R, Tai DI, et al. A one‐year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998 ; 339: 61–68. MEDLINE
19. 19 Dienstag J, Schiff E, Wright T, Perillo R, Hann HW, Crowther L, et al. Lamivudine treatment for one year in previously untreated US hepatitis B patients: Histologic improvement and hepatitis B e antigen (HBeAg) seroconversion [abstract]. Gastroenterology 1998 ; 114: 1235A.
20. 20 Grellier L, Mutimer S, Ahmed M, Brown D, Burrough AK, Rolles K, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996 ; 348: 1212–1215. MEDLINE
21. 21 Perrilo R, Rakela J, Martin P, Levy G, Schiff E, Wright T, et al. Lamivudine for hepatitis B after liver transplantation (OLT) [abstract]. Hepatology 1996 ; 24: 182A.
22. 22 Markowitz J, Pakrasi A, Hollis P, Martin P, Goldstein L, Busuttil R. Efficacy of lamivudine for prophylaxis and treatment of hepatitis B in liver transplant patients [abstract]. Hepatology 1996 ; 24: 182A.
23. 23 Allen MI, Deslaurier M, Andrews CW. Identification and characterization of mutation in hepatitis B virus resistant to lamivudine. Hepatology 1998 ; 27: 1670–1677. MEDLINE
24. 24 Ling R, Mutimer D, Ahmed M. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996 ; 3: 711–713.
25. 25 Aye TT, Bartholomeusz A, Shaw T. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997 ; 26: 1148–1153. MEDLINE
26. 26 Bartholomew MM, Jansen RW, Jeffers LJ. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997 ; 9044: 20–22.
27. 27 Dodson SF, Balan V, Shakil O, Bonham A, Rakela J, Fung JJ. Lack of efficacy of lamivudine for HBV infection after liver transplantation [abstract]. Hepatology 1998 ; 28: 262A.
28. 28 Wainberg MA, Salomm H, Gu Z. Development of HIV‐1 resistance to 2′3′‐dideoxy‐3′‐thiacytidine in patients with AIDS or advanced AIDS‐related complex. AIDS 1995 ; 9: 351–357. MEDLINE
29. 29 Tisdale M, Kemp SD, Parry NR. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′thicytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A 1993 ; 90: 5653–5656. MEDLINE
30. 30 Villamil E, Kuhn M, Makowka L, Podesta L, Howard T, Sher L, et al. Quantitative anti‐HBs titers during intramuscular (IM) hepatitis B immunoglobulin (HBIG) administration post–liver transplantation (LT) for hepatitis B [abstract]. Hepatology 1992 ; 16: 49A.
31. 31 Markowitz JS, Martin P, Conrad AJ, Markman JL, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using lamivudine and hepatitis B immune globulin. Hepatology 1998 ; 28: 585–589. MEDLINE
32. 32 Terrault NA, Wright TL, Roberts JP, Ascher NL. Combined short‐term hepatitis B immunoglobulin (HBIG) and long‐term lamivudine (LAM) versus HBIG monotherapy as hepatitis B virus (HBV) prophylaxis in liver transplant recipients [abstract]. Hepatology 1998 ; 28: 389A.
33. 33 Dodson SF, Balan V, Shakil O, Bonham A, Rakela J, Fung JJ. Substitution of lamivudine for long‐term HBIG after liver transplantation for hepatitis B–related liver disease [abstract]. Hepatology 1998 ; 28: 262A.
34. 34 McCaughan G, Koorey D, Spencer J, Verran D, Chui AKK, Sheil AGR, et al. Prophylactic lamivudine and very low‐dose HBIG prevent HBV recurrence post–liver transplant whilst rescue therapy with lamivudine is associated with significant resistance and graft loss [abstract]. Hepatology 1998 ; 28: 263A.